Protalix is a publicly traded biotechnology company (NYSE Amex: PLX), that is producing recombinant therapeutic proteins through the ProCellEx™ plant cell system.

INVESTOR RELATIONS:

Thank you for interest in Protalix Biotherapeutics. For questions and comments, please feel free to contact us at the addresses listed below.

Investor Relations

Marcy Nanus
The Trout Group LLC
740 Broadway, 9th Floor
New York, NY 10003
T:   646-378-2927
F:  646-378-2901
E:   


Brad Miles
BMC Communications Group, LLC
T:   212-477-9007 x17
E:   

General

Yossi Maimon, CFO

Protalix Biotherapeutics
2 Snunit St., Science Park,
POB 455, Karmiel 20100, Israel.

T:  +972-4-902-8100, Extension 143
F:  +972-4-988-9489
E:   


© 2007 Protalix Biotherapeutics. All Rights Reserved.